Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Adaptive Dose-Ranging, Multi-Center, Single-Blind, Double-Dummy, Active-Controlled Trial to Determine the Target Dose of Canakinumab (ACZ885) in the Treatment of Acute Flares in Gout Patients Who Are Refractory or Contraindicated to NSAIDs and/or Colchicine.

Next Previous
Trial Profile

An Adaptive Dose-Ranging, Multi-Center, Single-Blind, Double-Dummy, Active-Controlled Trial to Determine the Target Dose of Canakinumab (ACZ885) in the Treatment of Acute Flares in Gout Patients Who Are Refractory or Contraindicated to NSAIDs and/or Colchicine.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canakinumab (Primary) ; Triamcinolone
  • Indications Gout; Gouty arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis

Most Recent Events

  • 23 Jun 2012 Planned patient number of extension trial (EudraCT2009-012316-40) changed from 300 to 320.
  • 23 Jun 2012 Planned patient number of extension trial (EudraCT2009-012316-40) changed from 300 to 320.
  • 25 Mar 2011 Acute flare and improves health-related quality-of-life results published in the Arthritis Research and Therapy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top